<DOC>
	<DOCNO>NCT00708292</DOCNO>
	<brief_summary>This Phase I-Ib/II , open-label , multicenter study AUY922 administer intravenously patient multiple myeloma determine maximum tolerate dose . The Phase II part investigate efficacy AUY922 patient multiple myeloma . Additionally , study include Phase Ib combination part AUY922 administer combination bortezomib , determine maximum tolerate dose combination drug patient multiple myeloma .</brief_summary>
	<brief_title>A Phase I-Ib/II Study Determine Maximum Tolerated Dose ( MTD ) AUY922 Alone Combination With Bortezomib , With Without Dexamethasone , Patients With Relapsed Refractory Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Patients must diagnosis active multiple myeloma . Phase I Phase II part : Patients must receive least 2 4 prior line therapy disease progress last therapy . Phase Ib part : Patients must receive 2 prior line therapy ( exclude dexamethasone single agent ) . ECOG Performance Status ≤ 2 . Patients must acceptable neutrophil platelet count well adequate kidney liver function . Patients must magnesium level low limit normal correctable supplement . Patients must willing able undergo bone marrow biopsy/aspirate . Able sign inform consent . Exclusion criterion : Prior treatment HSP90 HDAC inhibitor treatment multiple myeloma . Patients unresolved diarrhea ≥ CTCAE grade 2 . Patients acute chronic liver disease . Patients use medication relative risk prolong QT interval . Clinically significant cardiac disease . Patients known disorder due deficiency bilirubin glucuronidation ( e.g . Gilbert 's syndrome ) . Pregnant lactating woman . Fertile woman childbearing potential ( WCBP ) use adequate contraception . Male patient whose partner WCBP , use adequate contraception . Patients unwilling unable comply protocol . Phase Ib part : Peripheral neuropathy ≥ CTCAE grade 1 . Phase Ib part : Prior treatment bortezomib . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>AUY922</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>HSP90 inhibitor</keyword>
	<keyword>Phase I/II</keyword>
</DOC>